Cancer clinical trials in the region Grand Est

222 currently recruiting clinical trials
Region Grand Est
Phase 1 / Phase 2 Lung cancer #NCT04939610 #2023-508995-12-01
Phase 2: Cancer du poumon non à petites celulles
NSCLC (Non-Small Cell Lung Cancer) Metastatic 1 2 Immunotherapy Chemotherapy
Systemic Treatment-Naive
CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy)
Novartis
Phase 1 / Phase 2 Pancreas cancer #NCT04939610 #2023-508995-12-01
Phase 2 - Cancer du pancréas
Adenocarcinoma Locally Advanced Metastatic None 1 2 Systemic Treatment-Naive Chemotherapy
CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy)
Novartis
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05875168 #2023-507937-14-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil (Strasbourg)
Daiichi Sankyo
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04104776 #2023-508002-20-00
Epithelial ovarian cancer Clear cell carcinoma Locally Advanced Metastatic ARID1A 1 2 3 or more
Systemic Treatment-Naive
ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
Constellation Pharmaceutique
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04585750 #2023-504251-27-00
Epithelial ovarian cancer Serous high grade carcinoma (HGSOC) Locally Advanced Metastatic TP53 1 2 3 or more
KRAS G12C KRAS non G12C Systemic Treatment-Naive
Institut de Cancérologie de Lorraine - Alexis Vautrin (Vandœuvre-lès-Nancy), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06923761 #2023-504845-30-00
Module 2 Partie D cancer colorectal pMMR/MSS
Locally Advanced Metastatic MSS/pMMR 1 2 3 or more
Systemic Treatment-Naive
ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer #NCT06923761 #2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma Locally Advanced Metastatic 1 2 Immunotherapy
Systemic Treatment-Naive
ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
Grey Wolf Therapeutics
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06923761 #2023-504845-30-00
Module 1 (Partie A, B, C) et module 2 (parties A et B) Tumeurs solides avancées
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
Grey Wolf Therapeutics
Phase 1 / Phase 2 Liver and bile duct cancer #NCT06923761 #2023-504845-30-00
Module 2 Cohorte 2 carcinome hépatocellulaire
Hepatocellular carcinoma Locally Advanced Metastatic Unhealthy A 1 2 Immunotherapy
Systemic Treatment-Naive
ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)
Grey Wolf Therapeutics